This presentation contain the technical analysis of Ranbaxy pvt. ltd. and its performance in the market.

1. RANBAXY PVT. LTD.
PRESENTED BY:
YAMINI SAPRA
VAISHALI DUBEY

3. INTRODUCTION OF RANBAXY:
Ranbaxy was incorporated in 1961 and went public in 1973.
Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company.
It is an integrated, research based, international pharmaceutical company, producing a wide
range of quality, affordable generic medicines, trusted by healthcare professionals and patients
across geographies.
The Company has a global footprint in 43 countries, world-class manufacturing facilities in 8
countries and serves customers in over 125 countries.
In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator
companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical
powerhouse.
The combined entity now ranks among the top 20 pharmaceutical companies, globally.

4. ORGANIZATION STRUCTURE:
Managing Director, Chairman & CEO : Malvinder Mohan singh
COO : Mr. Atul Sobti
President: Takashi Shoda
Director: Tsutomu Une
Managing Director: Sunil Godhwani

5. HISTORY:
1961= Company incorporated
1973= Ranbaxy goes public
1977=Ranbaxy first joint venture in Lagos (Nigeria) is setup
1983= A modern dosage forms facility at Dewas (MP) in India goes on Stream.
1990= Ranbaxy granted its first US Patent, for doxycline
1994= Estabilished regional headquarters in UK and USA . Listed in Luxenburg stock exchange
2000= forays in to Brazil, the largest pharmaceutical market in South America.
2005=Launches operations in Cannada.
2011= Celebrates golden jubilee year

6. PRODUCTS OFFERED:
 ANTI – INFECTION
 G.I & NUTRITIONALS
 CVS & DIABETES
 CNS
 NS AID & RELATED
 ANTI ALLERGANTS
 ANTI RETROVIRALS
 UROLOGY
 OTHERS

7. COMPITITORS:
SUN PHARMA
Dr. REDDYS LABS
LUPIN PHARMACEUTICALS
GLOXOSMITHKLINE

8. FINANCIAL POSITION:

10. FINANCIAL ANALYSIS:

11. INTERPRETATION:
This financial analysis of the company is 5 years from 30-3-10 to 30-3-15 which that there are so
many fluctuation occur in the company and in 2010 to 2011 the company increase its value
continuously but after 2011 the company faces continuous downfall in its share and it goes
down till 2014 but after 2014 the company’s share price going up but after march 2015 the
company stop to trading in NSE and BSE.

12. FUTURE PROSPECTS OF RANBAXY:
Achieving customer satisfaction is fundamental to a business.
Provide products and services of the highest quality.
Ensure profitability growth and enhance wealth of the shareholders.
Manage our operations with high concern for safety and environment.
Be a responsible corporate citizen.

13. CONCLUSION:
Now the Ranbaxy take over by Daiichi Sankyo the Japanese pharmaceuticals company on April,
7 2014 because they are continuously going down and they was not delivering enough
products, the generic market was not generating adequate returns so they have three choices
that if they should spends lots of money for come back in the market or they shot down there
company and other one is to expect the proposal of the Daiichi to merge with it.
So it is a win-win kind of for both the companies.